search
Back to results

Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QT-IOP) (QT-IOP)

Primary Purpose

Premature Ovarian Insufficiency

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Hormone replacement therapy:effect on ventricular repolarization
ECG
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Premature Ovarian Insufficiency focused on measuring Premature ovarian insufficiency, QTc, Torsade de pointe, Hormone replacement therapy

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

Patients with POI

  • Patient aged 18 to 40 years
  • Patient with POI diagnostic criteria (FSH >25UI/l twice at intervals of a few weeks) with amenorrhea
  • No hormone treatment interacting with the gonadotropic axis for at least one month before inclusion
  • Patient who has signed informed consent
  • Patient affiliated to a social security system

Healthy volunteers (including POI control group)

  • Healthy women, aged 18 to 40 years, age-matched (+/- 5 years), and by BMI class (BMI<18, 18-25, 25-30, 30-35, 35-40, >40) compared to women with BPI
  • Women with regular cycles of 26 to 32 days
  • Women who has signed an informed consent form
  • Patient affiliated to a social security system

Exclusion Criteria:

Patients with POI

  • Patient on HRT during the 1st evaluation
  • Pregnant or breastfeeding woman
  • Treatment regimen known to lengthen QT or act on ventricular repolarization
  • Cardiac history in particular cardiac rhythm disorder
  • Diabetes
  • Patient on AME (unless derogation from affiliation),
  • Severe renal insufficiency (MDRD <30ml/min/m²)

Healthy volunteers (including POI control group)

  • Diabetes or any chronic disease (including cardiovascular and endocrine)
  • Pregnant or breastfeeding woman
  • Hormonal contraceptive treatment in progress or stopped less than 3 months ago
  • Chronic treatment affecting the duration of QTc
  • Woman under AME (unless affiliation derogation)

Sites / Locations

  • BACHELOTRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Premature ovarian insufficiency

healthy volunteers

Arm Description

60 patients with POI followed in the endocrinology department

60 healthy volunteers matched with POI's patients

Outcomes

Primary Outcome Measures

Duration of QTc
Compare the duration of QTc in patients with non-substituted POI with that of matched healthy volunteers on cardiovascular risk factors. The QTc will be measured by the Fridericia method

Secondary Outcome Measures

Duration of QTc
Measure the duration of QTc in women with POI before and after the introduction of HRT
Duration of QTc
Study the association between sex hormone levels (gonadotropins, steroid hormones) and QTc duration, as well as their variation in patients with POI and healthy volunteers

Full Information

First Posted
September 26, 2019
Last Updated
October 15, 2021
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT04167033
Brief Title
Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QT-IOP)
Acronym
QT-IOP
Official Title
Study of Ventricular Repolarization in Patients With Premature Ovarian Insufficiency and Influence of Estrogen-progestin Replacement Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Recruiting
Study Start Date
April 14, 2021 (Actual)
Primary Completion Date
December 15, 2023 (Anticipated)
Study Completion Date
June 12, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Ventricular repolarization, measured by corrected QT interval (QTc), is influenced by sex hormones. A QTc above 460msec predisposes to the risk of "torsades-de-pointes"(TdP). The investigators have recently shown that estradiol determines an increase in QTc elongation and progesterone shortens it. In addition, high gonadotropin levels (FSH or LH) are associated with QTc prolongation. Hypergonadotropic hypogonadisms (low progesterone and high gonadotropins) are therefore hormonal situations that promote QTc prolongation. Premature ovarian insufficiency (POI) is one of them. Its management is based on the prescription of hormone replacement therapy (HRT). Epidemiological studies have shown that these patients would be at increased risk of cardiovascular mortality. Our team is interested in the effect of this pathological hormonal situation and its HRT on ventricular repolarization in order to define whether this is a population at risk for long QTc.
Detailed Description
Ventricular repolarization, measured by the duration of the heart rate corrected QT interval (QTc), is influenced by sex hormones. A QTc above 460msec predisposes to the risk of torsades-de-pointes (TdP); ventricular arrhythmias that can lead to sudden death. From puberty to menopause, QTc is longer in women than in men (~10-15msec difference) and varies in women according to the menstrual cycle (~5-10msec). This explains the increased risk of TdP in women compared to men. During the menstrual cycle, the risk is highest for women during the follicular phase compared to the luteal phase. The investigators have recently shown that estradiol determines an increase in QTc elongation and progesterone shortens it. In addition, high gonadotropin levels (FSH or LH) are associated with QTc prolongation. Hypergonadotropic hypogonadisms (low progesterone and high gonadotropins) are therefore hormonal situations that promote QTc prolongation. Premature ovarian insufficiency (POI) affects 1% of women under 40 years of age and is characterized by hypergonadotropic hypogonadism. POI is associated with hormonal deficiencies responsible for amenorrhea and infertility. Management is based on the prescription of hormone replacement therapy (HRT). Epidemiological studies have shown that these patients would be at increased risk of cardiovascular mortality. HRT will be based on the combination of an estrogen and a progestin and will lead to a variable decrease in gonadotropins, depending on the steroid hormones/doses used. Our team, after structuring one of the largest international cohorts of patients with POI, is interested in the effect of this pathological hormonal situation and its HRT on ventricular repolarization to define whether this is a population at risk for long QTc. Indeed, ECG follow-up is recommended and many drugs (cardiovascular or not), are to be avoided, or even contraindicated in situations at risk of long QTc.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Ovarian Insufficiency
Keywords
Premature ovarian insufficiency, QTc, Torsade de pointe, Hormone replacement therapy

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a bicentric case-control study: 60 patients with POI followed in the endocrinology department, and 60 healthy volunteers matched with POI's patients on age (+/- 5 years), on BMI classes (BMI<18, 18-25, 25-30, 30-35, 35-40, >40) and with regular cycles (26 to 32 days).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Premature ovarian insufficiency
Arm Type
Experimental
Arm Description
60 patients with POI followed in the endocrinology department
Arm Title
healthy volunteers
Arm Type
Other
Arm Description
60 healthy volunteers matched with POI's patients
Intervention Type
Drug
Intervention Name(s)
Hormone replacement therapy:effect on ventricular repolarization
Intervention Description
Hormone replacement therapy and QTc measurement
Intervention Type
Diagnostic Test
Intervention Name(s)
ECG
Intervention Description
QTc measurement
Primary Outcome Measure Information:
Title
Duration of QTc
Description
Compare the duration of QTc in patients with non-substituted POI with that of matched healthy volunteers on cardiovascular risk factors. The QTc will be measured by the Fridericia method
Time Frame
in the luteal phase between Day22 and Day25
Secondary Outcome Measure Information:
Title
Duration of QTc
Description
Measure the duration of QTc in women with POI before and after the introduction of HRT
Time Frame
the day before and between Day22 and Day60 after the introduction of HRT
Title
Duration of QTc
Description
Study the association between sex hormone levels (gonadotropins, steroid hormones) and QTc duration, as well as their variation in patients with POI and healthy volunteers
Time Frame
in the luteal phase between Day22 and Day25

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with POI Patient aged 18 to 40 years Patient with POI diagnostic criteria (FSH >25UI/l twice at intervals of a few weeks) with amenorrhea No hormone treatment interacting with the gonadotropic axis for at least one month before inclusion Patient who has signed informed consent Patient affiliated to a social security system Healthy volunteers (including POI control group) Healthy women, aged 18 to 40 years, age-matched (+/- 5 years), and by BMI class (BMI<18, 18-25, 25-30, 30-35, 35-40, >40) compared to women with BPI Women with regular cycles of 26 to 32 days Women who has signed an informed consent form Patient affiliated to a social security system Exclusion Criteria: Patients with POI Patient on HRT during the 1st evaluation Pregnant or breastfeeding woman Treatment regimen known to lengthen QT or act on ventricular repolarization Cardiac history in particular cardiac rhythm disorder Diabetes Patient on AME (unless derogation from affiliation), Severe renal insufficiency (MDRD <30ml/min/m²) Healthy volunteers (including POI control group) Diabetes or any chronic disease (including cardiovascular and endocrine) Pregnant or breastfeeding woman Hormonal contraceptive treatment in progress or stopped less than 3 months ago Chronic treatment affecting the duration of QTc Woman under AME (unless affiliation derogation)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Bissery, MD
Phone
1 42 16 24 32
Ext
+33
Email
anne.bissery@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Fredy Pene, Mr
Phone
1 42 16 24 35
Ext
+33
Email
fredy.pene@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Bachelot, Pr
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Joe Elie Salem, MD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Study Director
Facility Information:
Facility Name
BACHELOT
City
Paris
ZIP/Postal Code
75013
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
BACHELOT Anne, Pr
Phone
01 42 16 02 46
Email
anne.bachelot@aphp.fr
First Name & Middle Initial & Last Name & Degree
DULON Jérôme
Phone
01 42 16 02 11
Email
jerome.dulon@aphp.fr

12. IPD Sharing Statement

Learn more about this trial

Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QT-IOP)

We'll reach out to this number within 24 hrs